Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c3/8d/ea/c38deaae-278e-5fcf-c4a7-116a3c805dee/mza_14347572037496190150.jpg/600x600bb.jpg
PHASE3
Soundcraft Media
16 episodes
1 week ago

A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.

Show more...
Life Sciences
Science
RSS
All content for PHASE3 is the property of Soundcraft Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.

Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/43370137/85db9c1eeb623e5e.jpg
The Silent Killer: Who has the killer apps? With Dimerix and PYC Therapeutics
PHASE3
24 minutes 40 seconds
1 year ago
The Silent Killer: Who has the killer apps? With Dimerix and PYC Therapeutics

We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS).

And we talk to PYC Therapeutics CEO Dr Rohan Hockings about how his company's tech actually works to treat polycystic kidney disease.  

Support the show

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

PHASE3

A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.